ONCY is the only company to offer a pancreatic cancer treatment that is targeting advanced or metastatic pancreatic cancer, in which the 1 year survival rate is only 10%.
"Several biotech developers have been making strides
against the deadly disease, including a new mRNA vaccine in the works from BioNTech SE (NASDAQ:BNTX), as well as promising drug-combo therapies from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Seagen Inc. (NASDAQ:SGEN), and better diagnostics from Myriad Genetics, Inc. (NASDAQ:MYGN) and Illumina, Inc. (NASDAQ:ILMN)."
The others have targeted the earlier and less aggressive stages of pancreatic cancer, where the 5 year survival rate is now around 12 %.